SavedAdd your journal

Journals / Medeniyet Medical Journal / 2022 / Cilt: 37 - Sayı: 2

Association of Epicardial Adipose Tissue Thickness with Cardiovascular Risk in Acromegaly

Akromegalide Epikardiyal Yağ Dokusu Kalınlığı ile Kardiyovasküler Risk Arasındaki İlişki

Sercin ÖZKÖK
Bülent CAN
Mumtaz TAKİR
Fatma OLCAY COSKUN
Pages
131–137
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Epicardial adipose tissue thickness was significantly increased in the acromegaly group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Acromegaly is a rare disease associated with increased mortality.
📊
Key Findings & Data:Methods: The study included 38 patients followed up with the diagnosis of acromegaly and 29 healthy controls.
💡
Conclusion & Impact:Epicardial adipose tissue thickness was significantly increased in the acromegaly group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Acromegaly is a rare disease associated with increased mortality. Reports on coronary artery disease in acromegaly are controversial. This study aimed to investigate the possible association of epicardial adipose tissue thickness with cardiovascular risk in patients with acromegaly. Methods: The study included 38 patients followed up with the diagnosis of acromegaly and 29 healthy controls. Patients with acromegaly were divided into controlled and uncontrolled acromegaly groups based on insulin-like growth factor-1 levels. Epicardial adipose tissue thickness measurements were obtained from chest computed tomography, and laboratory data were extracted from patient files. Results: Twenty-nine patients (76.3%) had controlled acromegaly. Eleven patients with acromegaly had diabetes mellitus (28.9%), 18 (47.4%) had hypertension, and 27 (71%) had a concomitant chronic disease. Epicardial adipose tissue thickness was significantly increased in the acromegaly group (p

Özet

Amaç: Akromegali, mortalitede artış ile seyreden nadir bir hastalıktır. Akromegalide koroner arter hastalığı görülmesi ile ilgili birbiriyle tezat yayınlar mevcuttur. Bu çalışmada, akromegali hastalarında epikardiyal yağ dokusu kalınlığı ile kardiyovasküler risk arasındaki olası ilişkiyi araştırdık. Yöntemler: Çalışmaya akromegali tanısı ile takip edilen 38 hasta ve 29 sağlıklı kontrol olgu grubu dahil edildi. Akromegali hastaları, insülin benzeri büyüme faktörü-1 seviyelerine göre kontrollü ve kontrolsüz akromegali olmak üzere iki gruba ayrıldı. Epikardiyal yağ dokusu kalınlığı ölçümleri bilgisayarlı toraks tomografisinden yararlanılarak yapıldı, laboratuvar verilerine hasta dosyalarından ulaşıldı. Bulgular: Yirmi dokuz hasta (%76,3) kontrollü akromegali idi. Akromegali hastalarının 11’inde diabetes mellitus (%28,9) ve 18’inde (%47,4) hipertansiyon mevcuttu. Eşlik eden kronik hastalığı olan 27 (%71) hasta vardı. Akromegali grubunda epikardiyal yağ dokusu kalınlığı anlamlı olarak artmıştı (p

🔖

Cite This Article

ÖZKÖK, S., CAN, B., TAKİR, M., COSKUN, F. O. (2022). Association of Epicardial Adipose Tissue Thickness with Cardiovascular Risk in Acromegaly. Medeniyet Medical Journal, Cilt: 37 - Sayı: 2, 131–137. https://ajindex.com/articles/579136

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary. 2017;20:4-9
  2. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf). 2008;69:347-58
  3. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16:294-302
  4. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-52
  5. Mosca S, Paolillo S, Colao A, et al. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol. 2013;167:1712-8
  6. Sharma MD, Nguyen AV, Brown S, Robbins RJ. Cardiovascular Disease in Acromegaly. Methodist DeBakey Cardiovasc J. 2017;13:64-7
  7. Akutsu H, Kreutzer J, Wasmeier G, et al. Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol. 2010;162:879-86
  8. Bogazzi F, Battolla L, Spinelli C, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007;92:4271-7
  9. Dutheil F, Gordon BA, Naughton G, et al. Cardiovascular risk of adipokines: a review. J Int Med Res. 2018;46:2082-95
  10. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-53
  11. Sousa JA, Mendonça MI, Serrão M, et al. Epicardial Adipose Tissue: The Genetics Behind an Emerging Cardiovascular Risk Marker. Clin Med Insights Cardiol. 2021;15:11795468211029244
  12. Nagy E, Jermendy AL, Merkely B, Maurovich-Horvat P. Clinical importance of epicardial adipose tissue. Arch Med Sci. 2017;13:864-74
  13. Davidovich D, Gastaldelli A, Sicari R. Imaging cardiac fat. Eur Heart J Cardiovasc Imaging. 2013;14:625-30
  14. Ozkan C, Altinova AE, Cerit ET, et al. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary. 2015;18:621-9
  15. Reyes-Vidal C, Fernandez JC, Bruce JN, et al. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab. 2014;99:4124-32
  16. Siervo M, Lara J, Celis-Morales C, et al. Age-related changes in basal substrate oxidation and visceral adiposity and their association with metabolic syndrome. Eur J Nutr. 2016;55:1755-67
  17. Pascot A,